Tag Archives: Enzyvant

FDA declines to approve Enzyvant regenerative therapy on manufacturing concerns

(Reuters) – Privately held drug developer Enzyvant said on Thursday the U.S. Food and Drug Administration declined to approve its regenerative tissue therapy for a rare immunodeficiency disorder and raised concerns about its manufacturing. The company was hoping to win its first approval for the therapy, RVT-802, aimed at treating congenital athymia, a disorder affecting… Read More »